Skip to main content

CORRECTION article

Front. Oncol., 27 February 2024
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1376408

Corrigendum: Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

This article is a correction to:

  1. Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

    1. Read original article
Youlong Wang&#x;Youlong Wang1†Qi Huang&#x;Qi Huang2†Guanqing Zhong&#x;Guanqing Zhong2†Jun LvJun Lv3Qinzhi GuoQinzhi Guo4Yifei MaYifei Ma5Xinjia Wang*Xinjia Wang5*Jiling Zeng*Jiling Zeng6*
  • 1Hainan Hospital of PLA General Hospital, Department of General Surgery, Haitang District, Sanya, China
  • 2Department of Clinical Laboratory, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
  • 3Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • 4Pancreas Center of Guangdong Provincial People’s Hospital, Guangzhou, China
  • 5Department of Spine Surgery, The Second Affiliated Hospital, Shantou University Medical College, Shantou, China
  • 6Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Center, Guangzhou, China

A Corrigendum on
Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

by Wang Y, Huang Q, Zhong G, Lv J, Guo Q, Ma Y, Wang X and Zeng J (2023) Front. Oncol. 13:1191611. doi: 10.3389/fonc.2023.1191611

In the published article, there was an error in affiliation 4. The affiliation previously stated “4Pancreas Center of Guangdong Provincial People’s Hospital, Guangzhou, China”, the corrected affiliation is: “4Pancreas Center of Guangdong Provincial People’s Hospital, Guangzhou, China”.

In the published article, there was an error in affiliation 6. The previous affiliation stated “6Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China”, the corrected affiliation is: “6Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Center, Guangzhou, China”.

In the published article, an author name was incorrectly written as Wang Youlong. The correct spelling is Youlong Wang.

In the published article, an author name was incorrectly written as Guangqing Zhong. The correct spelling is Guanqing Zhong.

In the published article, the author contributions section was incorrectly written as “WY, QH, GZ, JL, QG, YM, XW, JZ contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript. All authors contributed to the article and approved the submitted version”. The corrected author contributions is “YW, QH, GZ, JL, QG, YM, XW, JZ contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript. All authors contributed to the article and approved the submitted version”.

In the published article, the funding was mistakenly not included in the publication. The missing funding appears below:

“This work was supported by the Science and Technology Special Fund of Guangdong Province of China [STKJ2023002]”.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: cancer of unknow primary, PET/CT (18)F-FDG, sunitinb, EFGR, VEGFR

Citation: Wang Y, Huang Q, Zhong G, Lv J, Guo Q, Ma Y, Wang X and Zeng J (2024) Corrigendum: Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment. Front. Oncol. 14:1376408. doi: 10.3389/fonc.2024.1376408

Received: 25 January 2024; Accepted: 26 January 2024;
Published: 27 February 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Wang, Huang, Zhong, Lv, Guo, Ma, Wang and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xinjia Wang, xj.wang2000@163.com; Jiling Zeng, cengjl@sysucc.org.cn

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.